New hope for myelofibrosis patients who stopped responding to standard treatment
Disease control
Recruiting now
This early-stage study is testing whether adding a new drug called roginolisib to the standard treatment ruxolitinib is safe and tolerable for adults with myelofibrosis, a serious bone marrow cancer. It aims to help patients whose disease has not responded well to ruxolitinib alo…
Phase: PHASE1, PHASE2 • Sponsor: iOnctura • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC